BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%

MT Newswires Live

09/18

BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.

The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.

The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.

BCAL Diagnostics shares rose 6% in morning trade on Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568441729"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568441729\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568441729?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568441729","market":"sg","top_or_hot":-1,"title":"BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-18 09:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"標普/澳交所 300指數","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568441729","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568441729","pubTimestamp":1758160198,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BCAL Diagnostics  partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","BK4211":"区域性银行","BCAL":"Bank of Southern California NA","BDX.AU":"BCAL DIAGNOSTICS LTD","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数"},"translate_title":"BCAL Diagnostics与美国诊断公司合作；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAL":1.5,"XJO.AU":0.82,"XKO.AU":0.82,"BDX.AU":1,"XAO.AU":0.82},"content_text":"BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}